Monty Rakusen Iovance Biotherapeutics (NASDAQ:IOVA) is going through a favorable moment which began in the second half of February following an accelerated FDA approval for its melanoma drug Amtagvi and the pricing of an underwritten offering. By analyzing the company foundations, we can underline that, beyond the approval by the regulator, there is an unsatisfied market demand regarding metastatic melanoma and that the company has developed and integrated its production capacity internally. It is also plan ...